TherapeuticsMD, Inc.

Equities

TXMD

US88338N2062

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-04-15 pm EDT 5-day change 1st Jan Change
1.95 USD -2.01% Intraday chart for TherapeuticsMD, Inc. -9.72% -13.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Knight Therapeutics Announces Launch of Bijuva in Canada MT
Knight Therapeutics Announces Product Launch For IMVEXXY In Canada MT
North American Morning Briefing : Stocks Seen Building on CPI Rally; PPI Data Due DJ
TherapeuticsMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
TherapeuticsMD, Inc. Announces Evaluation of Strategic Alternatives CI
TherapeuticsMD, Inc. Announces Executive Changes CI
TherapeuticsMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Growth Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Value Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Value Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Growth Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Index CI
TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
TherapeuticsMD, Inc. announced that it expects to receive $5 million in funding from Rubric Capital Management LP CI
TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TherapeuticsMD, Inc. Auditor Raises 'Going Concern' Doubt CI
North American Morning Briefing : Stocks Seen -2- DJ
North American Morning Briefing : Traders Reassess -2- DJ
North American Morning Briefing : Some Calm -2- DJ
Cantor Fitzgerald Reinstates TherapeuticsMD at Neutral With $5 Price Target MT
TherapeuticsMd, Inc. Announces Chief Executive Officer Changes CI
TherapeuticsMd, Inc. Announces Executive Changes CI
Chart TherapeuticsMD, Inc.
More charts
TherapeuticsMD, Inc. is a healthcare company. The Company is focused on developing and commercializing products exclusively for women. It is engaged in conducting business by out-licensing its products and collecting royalties, after granting a license to commercialize the Company's IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and its possessions and territories and assigning the Company’s exclusive license to commercialize ANNOVERA in the United States and its possessions and territories to Mayne Pharma. ANNOVERA is a one-year (13 cycles) ring-shaped contraceptive vaginal system (CVS)). ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone (SA) and ethinyl estradiol (EE). Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia.
More about the company
  1. Stock Market
  2. Equities
  3. TXMD Stock
  4. News TherapeuticsMD, Inc.
  5. Insider Trends: Insider Buying Continued with Purchase of TherapeuticsMD Shares